Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of SPN-812 for the Treatment of Pediatric Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT02736656 is registered in ClinicalTrials.gov with Supernus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02736656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02736656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of SPN-812 for the Treatment of Pediatric Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)
Lead sponsor
Supernus Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 2, 2016
Completion date
September 30, 2026
Enrollment
1,400 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

attention-deficit/hyperactivity disorder